GlassScriptPhysician profile
Javier Dieguez
NPI 1497061527
$12,056.24
in general payments reported to CMS, 2019-2025
41 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,875 · 2020: $529 · 2021: $729 · 2022: $1,036 · 2023: $5,165 · 2024: $1,113 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,954 · Education: $3,081 · Travel and Lodging: $852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,954.04 |
| Education | $3,080.86 |
| Travel and Lodging | $852.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,852.11 | 2023 | Ion, Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $2,714.56 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $970.94 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $491.95 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $437.40 | 2019-2025 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $407.04 | 2019-2025 | Ofev, Jascayd |
| Mylan Specialty L.P. | $342.97 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $325.48 | 2021-2025 | Glassia, Aralast |
| Genzyme Corporation | $273.97 | 2019-2025 | |
| Insmed, INC. | $231.08 | 2019-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $207.87 | 2022-2025 | Opsumit, Opsynvi |
| Advanced Respiratory, INC | $170.34 | 2019-2020 | |
| Grifols USA, LLC | $133.68 | 2021-2025 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $123.87 | 2019-2020 | |
| Amgen INC. | $118.58 | 2021-2025 | Tezspire |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Dieguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.